Trial Information

Topoisomerase 2 Expression and Acute Myeloid Leukemia (AML)

OBJECTIVES:

- Estimate the distributions of topoisomerase 2 (TOP2) expression and single nucleotide
polymorphisms (SNPs) in patients with newly diagnosed acute myeloid leukemia (AML).

- Estimate the distributions of mutations in TOP2 phosphorylation sites (by SNP analysis)
in these patients.

- Investigate whether expression of TOP2 or mutations in TOP2 phosphorylation sites vary
with patient or disease characteristics in these patients.

- Test whether TOP2 expression correlates with complete remission rates, relapse-free
survival, and overall survival of these patients.

- Conduct preliminary analyses to estimate the distributions of TOP2 expression and
mutations in TOP2 phosphorylation sites (by SNP analysis) in patients with relapsed
and/or refractory AML.

- Investigate whether expression of TOP2 and mutations in TOP2 phosphorylation sites vary
with patient or disease characteristics in patients with relapsed and/or refractory
AML.

- Test whether TOP2 expression and mutations in TOP2 phosphorylation sites differ between
previously untreated and relapsed/refractory AML patients.

OUTLINE: This is a multicenter study.

Archived RNA specimens are analyzed for topoisomerase 2 transcriptional expression by
quantitative real-time polymerase chain reaction (PCR) and for mutations within TOP2
phosphorylation sites by single nucleotide polymorphism analysis.